Auxesis Pharma strengthens its patent portfolio – new European patent application registered

Auxesis Pharma has taken another important step in the company’s development by filing a new European patent application related to its pharmaceutical technology.

The application was registered with the European Patent Office (EPO) in March 2026 and forms part of the company’s continued efforts to strengthen its intellectual property protection.

Continued development of technology and formulation

The patent application covers further development of the company’s formulation and technical solutions, with a focus on:

• enhancing stability and efficacy
• enabling broader areas of application
• strengthening commercial potential

This is in line with Auxesis Pharma’s strategy to continuously develop and protect its technology as the project moves closer to the clinical and commercial phase.

A central part of the company’s value creation

A strong patent portfolio is a crucial factor in pharmaceutical development and constitutes an important part of the company’s long-term value creation.

The new application complements previously filed patents and strengthens the company’s position ahead of upcoming clinical studies and market establishment.

Next steps

In parallel with the patent work, the company continues according to plan with:

• regulatory processes
• preparations for clinical studies
• development toward market approval

Comment

Continuously strengthening our patent protection is a natural part of our development. It not only safeguards our technology, but also creates a solid foundation for future commercialization.

– Auxesis Pharma